


# FRONTIERS IN COMPUTATIONAL CHEMISTRY



Editors:  
Zaheer Ul-Haq  
Angela K. Wilson

**Bentham Books**

# **Frontiers in Computational Chemistry**

*(Volume 5)*

**Edited by**

**Zaheer Ul-Haq**

*Dr. Panjwani Center for Molecular Medicine & Drug  
Research,  
International Center for Chemical & Biological Sciences,  
University of Karachi,  
Karachi,  
Pakistan*

**&**

**Angela K. Wilson**

*Department of Chemistry,  
Michigan State University,  
East Lansing, MI,  
USA*

## **Frontiers in Computational Chemistry**

*Volume # 5.*

Editors: Zaheer Ul-Haq and Angela K. Wilson

ISSN (Online): 2352-9458

ISSN (Print): 2352-944X

ISBN (Online): 978-981-14-5779-1

ISBN (Print): 978-981-14-5777-7

ISBN (Paperback): 978-981-14-5778-4

©2020, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

PREFACE .....	i
LIST OF CONTRIBUTORS .....	iii
<b>CHAPTER 1 RECENT ADVANCES AND ROLE OF COMPUTATIONAL CHEMISTRY IN DRUG DESIGNING AND DEVELOPMENT ON VIRAL DISEASES</b> .....	1
<i>Co k'Nqej cd.'Tcnj k'Vj ct glc.'Ukpi ggc'F0l cft g'and'Tggpc'Uczgpc</i>	
<b>INTRODUCTION</b> .....	2
<b>STRUCTURE-BASED COMPUTATIONAL METHODS IN DRUG DESIGNING</b> .....	4
Finding the Target Structure .....	4
Pharmacophore Modeling .....	7
Ligand Docking .....	9
De Novo Design .....	11
<b>LIGAND BASED COMPUTATIONAL METHODS IN DRUG DESIGNING</b> .....	12
Quantitative Structure Activity Relationships (QSAR) .....	13
Pharmacophore Modeling .....	15
Virtual Screening .....	16
Scaffold Hopping .....	17
<b>MULTI TARGET DRUG DESIGNING</b> .....	19
<b>ROLE OF QUANTUM AND MOLECULAR MECHANICS IN DRUG DESIGNING</b> .....	20
Homology Modeling .....	20
Molecular Dynamic Simulations .....	22
<i>Molecular Mechanics Force Fields (MM2, MM3 and MM4)</i> .....	24
<i>Merck Molecular Force Field (MMFF)</i> .....	24
<i>Universal Force Field (UFF)</i> .....	24
<i>Chemistry at Harvard Molecular Mechanics (CHARMM)</i> .....	25
<i>Assisted Model Building with Energy Refinement (AMBER)</i> .....	25
Quantum/Molecular Mechanics .....	26
Fragment Molecular Orbital Method .....	27
<b>A BRIEF OVERVIEW OF THE ROLE OF CADD IN THE DEVELOPMENT OF DRUGS AGAINST VIRAL DISEASES</b> .....	28
Ebola Virus .....	28
Zika Virus .....	33
Hepatitis C Virus .....	37
Coronavirus .....	41
<b>FUTURE PERSPECTIVE</b> .....	48
<b>CONSENT FOR PUBLICATION</b> .....	49
<b>CONFLICT OF INTEREST</b> .....	49
<b>ACKNOWLEDGEMENTS</b> .....	49
<b>REFERENCES</b> .....	49
<b>CHAPTER 2 MOLECULAR MODELING APPLIED TO DESIGN OF CYSTEINE PROTEASE INHIBITORS – A POWERFUL TOOL FOR THE IDENTIFICATION OF HIT COMPOUNDS AGAINST NEGLECTED TROPICAL DISEASES</b> .....	63
<i>Igor José dos Santos Nascimento, Thiago Mendonça de Aquino, Paulo Fernando da Silva Santos-Júnior, João Xavier de Araújo-Júnior and Edeildo Ferreira da Silva-Júnior</i>	
<b>INTRODUCTION</b> .....	64
<b>VIRTUAL SCREENING IN DRUG DEVELOPMENT</b> .....	65
<b>CYSTEINE PROTEASES AND THEIR CATALYTIC MECHANISM</b> .....	67
<b>MOLECULAR MODELING APPLIED TO THE DESIGN OF CYSTEINE PROTEASE INHIBITORS</b> .....	70

Trypanosoma cruzi (Cruzain) .....	70
Plasmodium falciparum (Falcipain) .....	78
Chikungunya (nsP2) .....	88
Schistosoma mansoni (SmHDAC8) .....	90
Other Cysteine Proteases .....	92
<i>Cathepsin Family</i> .....	92
<i>Enterovirus 71 (3Cpro) and Coronavirus (3CLpro)</i> .....	96
<i>Caspase Family</i> .....	98
<b>CRITICAL STEPS AND LIMITATIONS OF VIRTUAL SCREENING CAMPAIGNS</b> .....	100
<b>CONCLUSION AND FUTURE OUTLOOK</b> .....	101
<b>CONSENT FOR PUBLICATION</b> .....	102
<b>CONFLICT OF INTEREST</b> .....	102
<b>ACKNOWLEDGEMENTS</b> .....	102
<b>REFERENCES</b> .....	102

<b>CHAPTER 3 APPLICATION OF SYSTEMS BIOLOGY METHODS IN UNDERSTANDING THE MOLECULAR MECHANISM OF SIGNALLING PATHWAYS IN THE EUKARYOTIC SYSTEM</b> .....	111
<i>Cfklc"Teq"UL0and"OORetco guj c</i> .....	
<b>INTRODUCTION</b> .....	112
Intercellular Signalling Pathways .....	112
<b>WHAT IS WNT?</b> .....	112
Types of Wnt Signalling Pathway .....	113
<b>CANONICAL PATHWAY</b> .....	113
$\beta$ -Catenin Dependent Canonical Pathway .....	113
$\beta$ -Catenin Independent Canonical Pathway .....	114
<b>NON-CANONICAL SIGNALLING PATHWAY</b> .....	116
Wnt/Planar Cell Polarity (PCP) Pathway .....	116
The Wnt/Ca <sup>2+</sup> Pathway .....	117
<b>SIGNIFICANCE OF THE WNT SIGNALLING PATHWAY</b> .....	118
<b>IMPORTANCE OF WNT PATHWAYS IN DEFENCE</b> .....	119
Wnt Pathways and Cancers .....	120
Wnt Pathways and Other Diseases .....	120
<b>APPLICATION OF COMPUTATIONAL METHODS TO UNDERSTAND SIGNALLING PATHWAYS</b> .....	122
General Concept and Principle of Pathway-based Analysis .....	122
Pathway and Network Analysis for Proteomics .....	124
Resources for Pathway-based Analysis .....	125
Application of Systems Biology Tools to Decipher WNT Signalling: Targeting Modulators of Wnt Signalling for Therapy .....	127
Inhibitors Blocking Fzd and Dvl Protein .....	128
Porcupine Enzyme Inhibitors .....	129
TNKS Enzyme Inhibitors .....	130
GSK-3 $\beta$ targeted inhibitors for the activation of Wnt signalling .....	130
Natural products as Wnt Inhibitors .....	131
<b>CONCLUSION</b> .....	132
<b>CONSENT FOR PUBLICATION</b> .....	132
<b>CONFLICT OF INTEREST</b> .....	133
<b>ACKNOWLEDGEMENTS</b> .....	133
<b>REFERENCES</b> .....	133

<b>CHAPTER 4 IMPLEMENTATION OF THE MOLECULAR ELECTROSTATIC POTENTIAL OVER GPUS: LARGE SYSTEMS AS MAIN TARGET</b> .....	149
<i>J. César Cruz, Ponciano García-Gutierrez, Rafael A. Zubillaga, Rubicelia Vargas and Jorge Garza</i>	
<b>INTRODUCTION</b> .....	149
<b>GRAPHICS PROCESSING UNITS IN QUANTUM CHEMISTRY</b> .....	151
<b>EVALUATING THE MEP USING QUANTUM CHEMISTRY METHODS</b> .....	152
<b>IMPLEMENTATIONS TO EVALUATE THE MOLECULAR ELECTROSTATIC POTENTIAL</b> .....	154
<b>FULL EVALUATION OF THE MEP</b> .....	155
<b>LINEAR SCALING TECHNIQUE</b> .....	159
<b>SCREENING OF THE MEP THROUGH SHORT- AND LONG-RANGE INTERACTIONS</b> .....	160
<b>EVALUATION OF THE MEP OVER GPUS</b> .....	164
<b>CONCLUSION</b> .....	168
<b>CONSENT FOR PUBLICATION</b> .....	169
<b>CONFLICT OF INTEREST</b> .....	169
<b>ACKNOWLEDGEMENTS</b> .....	169
<b>REFERENCES</b> .....	169
<b>CHAPTER 5 MOLECULAR ELECTRON DENSITY THEORY: A NEW THEORETICAL OUTLOOK ON ORGANIC CHEMISTRY</b> .....	174
<i>Luis R. Domingo and Nivedita Acharjee</i>	
<b>INTRODUCTION</b> .....	175
<b>CONCEPTUAL DENSITY FUNCTIONAL THEORY (CDFT) INDICES</b> .....	177
Global CDFT Indices .....	178
<i>Electronic Chemical Potential (<math>\mu</math>)</i> .....	178
<i>Chemical Hardness (<math>\eta</math>) and Softness (<math>S</math>)</i> .....	178
<i>Electrophilicity Index (<math>\omega</math>)</i> .....	179
<i>Nucleophilicity Index (<math>N</math>)</i> .....	181
Local CDFT Indices .....	183
<i>Fukui Functions</i> .....	183
<i>Parr Functions</i> .....	185
Reactivity Indices for Free Radicals .....	187
<b>LEWIS-LIKE STRUCTURE FROM TOPOLOGICAL ANALYSIS OF ELECTRON LOCALIZATION FUNCTION (ELF)</b> .....	189
<b>EXPLORING THE POTENTIAL ENERGY SURFACE (PES)</b> .....	192
<b>GLOBAL ELECTRONIC FLUX IN THE LOWERING OF ACTIVATION ENERGIES: THE GEDT CONCEPT</b> .....	194
<b>REVEALING THE MECHANISM AND ELECTRON DENSITY TRANSFER BY BONDING EVOLUTION THEORY</b> .....	196
<b>REVEALING THE ELECTRON DENSITY DISTRIBUTION BY BADERS' THEORY OF ATOMS IN MOLECULES</b> .....	200
Topological Analysis of the Electron Density Distribution and Search for Critical Points ...	200
The Sign of Laplacian of Electron Density .....	202
NCI Gradient Isosurfaces .....	203
QTAIM Topological Analysis Performed Under MEDT .....	204
<b>APPLICATIONS OF MOLECULAR ELECTRON DENSITY THEORY</b> .....	205
Diels-Alder Reactions .....	205
Electrocyclic Reactions and Sigmatropic Rearrangements .....	207
[3+2] Cycloaddition Reactions .....	208



CONCLUSION .....	217
CONSENT FOR PUBLICATION .....	218
CONFLICT OF INTEREST .....	218
ACKNOWLEDGEMENTS .....	218
REFERENCES .....	218
<b>CHAPTER 6 FRONTIER MOLECULAR ORBITAL APPROACH TO THE CYCLOADDITION REACTIONS .....</b>	<b>228</b>
<i>Anjandeeep Kaur</i>	
INTRODUCTION .....	228
1,3-DIPOLE/YLIDE .....	230
Classification of 1,3-Dipoles .....	230
<i>Allyl Anion Type 1,3-Dipoles</i> .....	230
<i>Propargyl/Allenyl Anion Type 1,3-Dipoles</i> .....	232
The Dipolarophile .....	233
Mechanism of 1,3-Dipolar Cycloaddition .....	233
Regioselectivity in 1,3-Dipolar Cycloaddition .....	237
Reactivity .....	245
CONCLUSION .....	247
CONSENT FOR PUBLICATION .....	247
CONFLICT OF INTEREST .....	247
ACKNOWLEDGEMENTS .....	247
REFERENCES .....	248
SUBJECT INDEX .....	252

## PREFACE

Computational chemistry is an important partner to experiment in understanding a very broad range of chemical problems, providing insight not possible or not easily possible to obtain via experiment, and enabling a greater understanding of experiment when it is possible. The span of computational chemistry approaches in terms of both method and applicability is significant – with methods including electronic structure calculations (*e.g.*, density functional theory (DFT)) and free energy relationships (*e.g.*, QSAR, QSPR), with applications spanning from in-depth description of the spectroscopic properties of the smallest of atoms and molecules to the design of new molecules and materials in medicine.

The focus of *Frontiers in Computational Chemistry* is on the application of computational chemistry approaches to biological and organic processes.

In this fifth volume, the six chapters address a diversity of topics including:

**Chapter 1 “Recent Advances and Role of Computational Chemistry in Drug Designing and Development on Viral Diseases”** Amit Lochab, Rakhi Thareja, Reena Saxena, Sangeeta D. Gadre.

This chapter outlines a number of approaches that are commonly used in drug design, including structural-based and ligand-based computational strategies, and the role of quantum mechanics and molecular mechanics. A brief overview of how these methods have been utilized in the development of drugs against viral disease, addressing ebola, zika, hepatitis C, and coronavirus is provided.

**Chapter 2 “Molecular Modeling Applied to Design of Cysteine Protease Inhibitors – A Powerful Tool for the Identification of Hit Compounds Against Neglected Tropical Diseases”** Igor José dos Santos Nascimento, Thiago Mendonça de Aquino, Paulo Fernando da Silva Santos-Júnior, João Xavier de Araújo-Júnior, and Edeildo Ferreira da Silva-Júnior.

The impact and importance of computational chemistry in drug development is significant. However, the drug discovery process is truly a fine art, with numerous methods and strategies available. In this chapter, the authors consider a number of different molecular modeling techniques, and demonstrate their use in the development of cysteine protease inhibitors. Cysteine proteases are known to play important roles from growth and development of plants to bone development in humans and animals. In this study, the design of cysteine protease inhibitors against a number of tropical diseases is considered.

**Chapter 3 “Application of Systems Biology Methods in Understanding the Molecular Mechanism of Signalling Pathways in the Eukaryotic System”**, Aditya Rao S.J. and M. Paramesha.

Signalling pathways are critical cascades of reactions that can impact metabolic functions from cell division to cell death. Understanding the underlying mechanisms of signalling pathways is critical, as this can provide insight about how abnormalities can impact the activation or deactivation of signalling events. The authors provide an overview of computational routes that can be used to understand signalling path mechanisms, including systems biology and data mining. Wnt signalling pathways are the focus of this chapter due to their role in growth to cancer.

Chapter 4 “**Implementation of the Molecular Electrostatic Potential over GPUs: Large Systems as Main Target**” J. César Cruz, Ponciano García-Gutierrez, Rafael A. Zubillaga, Rubicelia Vargas and Jorge Garza.

Electrostatic interactions are vital to non-covalent interactions which are prevalent in biological systems. A very useful means to gain insight about these electrostatic interactions is via the molecular electrostatic potential (MEP). MEP is generated using quantum mechanical methods, which represents a significant computational challenge for all but the smallest of molecules. This chapter provides two routes to extend the utility of MEP to larger molecules, utilizing graphical processing units (GPUs) to generate the MEP. The theoretical details are provided, as are a number of useful examples of the application of the methods.

Chapter 5 “**Molecular Electron Density Theory: A New Theoretical Outlook on Organic Chemistry**” Luis R. Domingo, Nivedita Acharjee.

This chapter highlights molecular electron density theory (MEDT), which was introduced by the co-author, Luis Domingo, in 2015. MEDT is based upon the philosophy that changes in electron density rather than molecular orbital interactions drive molecular reactions. The authors discuss a broad range of quantum mechanical principles and approaches that are a part of MEDT and facilitate the understanding of molecular interactions and reactions. The authors provide a long list of reactions, and conclusions that can be drawn from MEDT about these reactions.

Chapter 6 “**Frontier Molecular Orbital Approach to the Cycloaddition Reactions**”, Anjandeeep Kaur.

Cycloaddition reactions, more specifically, 1,3-dipolar cycloaddition reactions, play a critical role from drug discovery to materials design. Controlling the regioselectivity, enantioselectivity, and diastereoselectivity of these reactions is a major challenge. In this chapter, the reactivity and selectivity of a wide variety of 1,3-dipolar cycloaddition reactions is overviewed. A Frontier Molecular Orbital (FMO) approach is considered.

We hope that the readers will find these reviews to be valuable, and that they may inspire trigger further research in the field. We are grateful for the timely efforts made by the editorial personnel, especially Ms. Mariam Mehdi (Assistant Manager Publications), Mr. Obaid Sadiq (Manager Bentham Books), and Mr. Mahmood Alam (Director Publications) at Bentham Science Publishers.

**Zaheer Ul-Haq**

Dr. Panjwani Center for Molecular Medicine and Drug Research  
International Center for Chemical and Biological Sciences  
University of Karachi  
Karachi  
Pakistan

**&**

**Angela K. Wilson**  
Department of Chemistry  
Michigan State University  
East Lansing, MI  
USA

## List of Contributors

<b>Amit Lochab</b>	Department of Chemistry, Kirori Mal College, University of Delhi, Delhi, India
<b>Aditya Rao S.J.</b>	Department of Plant Cell Biotechnology, CSIR-Central Food Technological Research Institute, Mysuru, India
<b>Anjandeeep Kaur</b>	Department of Chemistry, Government Mohindra College Patiala, Patiala, India
<b>Edeildo Ferreira da Silva-Júnior</b>	Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil
<b>Igor José dos Santos Nascimento</b>	Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil
<b>João Xavier de Araújo-Júnior</b>	Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil
<b>J. César Cruz</b>	Departamento de Química, Universidad Autónoma Metropolitana-Iztapalapa, México
<b>Jorge Garza</b>	Departamento de Química, Universidad Autónoma Metropolitana-Iztapalapa, México
<b>Luis R. Domingo</b>	Department of Organic Chemistry, University of Valencia, Valencia, Spain
<b>M. Paramesha</b>	Department of Plant Cell Biotechnology, CSIR-Central Food Technological Research Institute, Mysuru, India Department of Food Technology, Davangere University, Karnataka, India
<b>Nivedita Acharjee</b>	Department of Chemistry, Durgapur Government College, West Bengal, India
<b>Paulo Fernando da Silva Santos-Júnior</b>	Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil
<b>Ponciano García-Gutierrez</b>	Departamento de Química, Universidad Autónoma Metropolitana-Iztapalapa, México
<b>Rakhi Thareja</b>	Department of Chemistry, St. Stephens College, University of Delhi, Delhi, India
<b>Rafael A. Zubillaga</b>	Departamento de Química, Universidad Autónoma Metropolitana-Iztapalapa, México
<b>Reena Saxena</b>	Department of Chemistry, Kirori Mal College, University of Delhi, Delhi, India
<b>Rubicelia Vargas</b>	Departamento de Química, Universidad Autónoma Metropolitana-Iztapalapa, México
<b>Sangeeta D. Gadre</b>	Department of Physics, Kirori Mal College, University of Delhi, Delhi, India
<b>Thiago Mendonça de Aquino</b>	Chemistry and Biotechnology, Federal University of Alagoas, Maceió, Brazil

# Recent Advances and Role of Computational Chemistry in Drug Designing and Development on Viral Diseases

Amit Lochab<sup>1</sup>, Rakhi Thareja<sup>2</sup>, Sangeeta D. Gadre<sup>3</sup> and Reena Saxena<sup>1,\*</sup>

<sup>1</sup> Department of Chemistry, Kirori Mal College, University of Delhi, Delhi, India

<sup>2</sup> Department of Chemistry, St. Stephens College, University of Delhi, Delhi, India

<sup>3</sup> Department of Physics, Kirori Mal College, University of Delhi, Delhi, India

**Abstract:** The growing number of contagious viral diseases among different geographic regions has become a threat to human health and the economy on a global scale. Various viral epidemics in the past have caused huge casualties due to lack of effective vaccine, the recent outbreak of COVID-19 is a good example of it. Drug designing and development is a lengthy, tedious and expensive process that is always associated with a high level of uncertainty as the success rate of their approval as a drug is very low. Computer-aided drug designing by utilizing *in silico* methods has shown prominent ways to develop novel drugs in a cost-efficient manner and has evolved as a rescue in the past few years. Interestingly, the highest FDA approval reached a maximum (59 drugs) in 2018 for which a lot of credit goes to the successful development of computational chemistry tools for drug designing in the last two decades. These methods provide better chances of getting hit compounds in a far more accurate and faster way. Drug designing is a cyclic optimization process that involves various steps like creating a molecule, selecting the target for this molecule, analysing the binding pattern and estimating the pharmacokinetics of the molecule. The final development of a drug candidate is cumulative of positive results obtained in each aforementioned step. Various computational techniques/approaches such as molecular dynamic studies, homology modelling, ligand docking, pharmacophore modelling and QSAR can be utilized in each phase of the drug discovery cycle. In this chapter, we aim to highlight the recent advances that have taken place in developing tools and methodologies that lead to *in silico* preparation of novel drugs against various viral infections like Ebola, Zika, Hepatitis C and Coronavirus.

**Keywords:** Computational chemistry, Homology modeling, *In Silico*, Ligand-based drug designing, Ligand docking, Multi target drug designing, Pharmacophore modeling, Protein target, Quantum mechanics, Structure-based drug designing, Viral infection, Virtual screening.

\* Corresponding author Saxena Reena: Department of Chemistry, Kirori Mal College, University of Delhi, Delhi, India; E-mails: rsaxena@kmc.du.ac.in; reenasax@hotmail.com

## INTRODUCTION

There is a huge global effort indulged in wiping out the infectious viral diseases. Viral infections include various contagious diseases like Ebola, Hepatitis, HIV-AIDS, Rabies, Zika and Corona viruses. These ailments cause a huge impact on both the economy and health. Methods in controlling these diseases like vaccination, public awareness through advertisement and campaigns cause a reduction in the budget which is not that effective also. The current available drugs for the disease have their own limitations of being toxic, less potent and high cost. There are several viral microbes that gain resistance toward these drugs and there is always a continuous need for developing new effective drugs. Studies show that the traditional path for discovering drugs and bringing it to market costs around 2 billion USD. In addition, they require a long time, and the process is highly laborious to establish their safety and effectiveness. At the starting of the 20<sup>th</sup> century, the drug industry was used to screen out various natural and synthetic compounds experimentally in search of therapeutic characteristics for a particular target. Then the compound was optimized for better pharmacological properties having less toxicity which after clinical trials used to take on an average of ~15 years to come in the market [1]. The concerns over various incurable diseases and an inadequate number of potent drugs have forced us to develop innovative drugs with high specificity and potency for the respective target. The ways in which these microbes are mutating their genes to make a come back in our world have proved to be hazardous in an irreparable fashion as is evident from the outbreak of the pandemic of Covid-19 in December, 2019. This has further added the interests of the researchers in fast and efficient drug discovery tools.

Drug discovery using computational chemistry is established very well from the past few years due to development in combinatorial chemistry with computational screening and optimizing tools, with enhanced, fast and efficacious results. The computational methods help in predicting the conformational interactions of active drugs with the target sites. High throughput screening (HTS) and Computer Aided Drug Discovery (CADD) techniques have helped in suggesting favourable drugs out of huge libraries in a short time by understanding the interaction between the target molecule and the proposed drug. The drug discovery process includes several computational approaches before the clinical trials, right from the beginning in which identification of target and their association with a particular disease is considered for studies. The second step is to investigate the interaction of proposed drug molecules with validated target which is followed by the optimization of lead molecules for the improvement in their potency and biological toxicity [2, 3].

This chapter aims to give an overview of different computational approaches and tools for the development in drug designing based on explanation from quantum mechanics. This covers various optimization procedures for enhancing potency of lead compounds. Finally, recent applications of CADD in designing drugs for viral diseases such as Ebola, Zika, Hepatitis C and Coronavirus are discussed.

The first modelling approach in computational drug development method is to identify the probable target related to particular disease. Generally, these targets can be proteins, enzymes or complex bio molecules having specific bioactivity. CADD can be divided into Structure based drug design (SBDD) and Ligand based drug design (LBDD) based on the availability of the structures of the above bio molecule targets as shown in Fig. (1). Both approaches are complimentary to each other as SBDD employs known structure of the target moiety for the screening of active new compounds. The structural information of target is used to find new lead compounds by suggesting a design of potent molecule or through screening from virtual libraries and databases. Whereas LBDD is a suitable approach, when the crystal structure of drug target is not available. However, one must clearly understand that SBDD is based on the drug-target structure where in the binding efficiency by a specific ligand/drug is given major importance which may be studied using several docking tools. On the other hand, LBDD makes use of ligands of the target *i.e.* potential drugs shortlisted to bind to the biological target of the drug [4].




Fig. (1). Computer-Aided Drug Design.

# Molecular Modeling Applied to Design of Cysteine Protease Inhibitors – A Powerful Tool for the Identification of Hit Compounds Against Neglected Tropical Diseases

Igor José dos Santos Nascimento<sup>1</sup>, Thiago Mendonça de Aquino<sup>1</sup>, Paulo Fernando da Silva Santos-Júnior<sup>1</sup>, João Xavier de Araújo-Júnior<sup>2</sup> and Edeildo Ferreira da Silva-Júnior<sup>1,2,\*</sup>

<sup>1</sup> Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil

<sup>2</sup> Laboratory of Medicinal Chemistry, Pharmaceutical Sciences Institute, Federal University of Alagoas, Maceió, Brazil

**Abstract:** Cysteine proteases play numerous and extremely important roles in the life cycle of parasitic organisms with medicinal importance. From general catabolic functions and protein processing, cysteine proteases may be key to parasite immunoevasion, excystment/encystment, and cell and tissue invasion. Parasite cysteine proteases are unusually immunogenic and have been exploited as serodiagnostic markers and vaccine targets. The research focused on the development of new drugs actives toward this macromolecular target is an important task, where the rational design is considered as a critical step on it. The discovery of new drugs is a complex and multidisciplinary process, which includes an in-depth knowledge of organic chemistry, pharmacology, biochemistry, computer sciences, and others. This process involves high costs and several scientific fields, leading to the necessity to develop new processes that involve optimization of molecular modeling applied to the identification of bioactive molecules. These techniques could increase the probability of obtaining a rational-designed compound, with high activity and safety, which could be considered as a potential drug in the future. Thus, the use of computational techniques has become increasingly common in medical chemistry laboratories due to their low costs and high correlation with experimental results from assays. A broadly used technique in the rational design of active compounds is molecular docking of small ligand at the active site from the biological targets. In this chapter, we will demonstrate in detail different molecular modeling techniques applied to the development of new inhibitors against cruzain (*Trypanosoma cruzi*); falcipain (*Plasmodium falciparum*); SmHDAC8 (*Schistosoma mansoni*); nsP2 (Chikungunya virus) enzymes; and others, such as cathepsin family; caspase family, 3C<sup>pro</sup> (Enterovirus 71) and 3CL<sup>pro</sup> (Coronavirus).

\* Corresponding author Edeildo Ferreira da Silva-Júnior: Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceió, Brazil; Tel: (+55)879-9610-8311; E-mail: edeildo.junior@esenfar.ufal.br



Finally, studies have revealed that the application of molecular modeling is a powerful tool for predicting new active and productive molecules against infectious diseases.

**Keywords:** Cysteine Proteases, Drug Discovery, Molecular Modeling, Neglected Tropical Diseases, Virtual Screening.

## INTRODUCTION

According to the World Health Organization (WHO), Neglected Tropical Diseases (NTDs) refer to a set of 20 bacterial, parasitic, or viral diseases involving vectors or hosts with complex life cycles. In 2018, NTDs affected about 1.5 billion individuals that are living in social exclusion and poverty in 149 different countries, representing 11% of all global diseases [1 - 3].

From 2012 to 2018, only 3.1% of all 256 approved new drugs were addressed to the NTDs' treatment [2, 4]. Among these, six approved drugs were obtained from drug repurposing based on *in silico* studies), new formulations or biological studies, evidencing a profound lack of interest in research addressed to the discovery of new drugs and treatments for such diseases [5 - 7]. Thus, the major reason for this lack of interest by pharmaceutical companies is related to the high financial costs for drug designing and development. Recently, it has been estimated that US\$ 3.4 million are necessary for the preclinical phase, increasing up to 8.6 and 21.4 million dollars in the II and III clinical phases, respectively. Finally, the low financial return generated by this type of pharmacotherapeutic agents is also a complex factor [8 - 11].

Considering this, the current trend of the drug discovery process remains on the combination of Computer-Assisted Drug Design (CADD) tools (*in silico* methods) and combinatorial chemistry and/or high-throughput screening (HTS) studies to improve the ability to discover promising agents or scaffolds [12, 13]. This trend reduces costs by decreasing the number of molecules to be tested, minimizes the possibility of failure due to physicochemical properties, and allows to comprehend the pharmacological mechanism at a molecular level [14 - 16].

The CADD strategy is subdivided into two large groups: Ligand-Based Drug Design (LBDD), in which all information about ligand structures and their biological activities are considered (*e.g.* Quantitative Structure-Activity Relationship (QSAR) and similarity modeling). In contrast, Structure-Based Drug Design (SBDD) considers information about the 3D-structure of biological targets and also ligands' structures (*e.g.* molecular docking and dynamics simulations) [13 - 15]. Moreover, the homology modeling (HM) is based on the production of an atomic model (as an SBDD method), built from the amino acid sequence of a

biomacromolecular target, as well as homologous proteins [17, 18]. In this context, CADD has become an essential and powerful tool for drug designing of new agents against NTDs. From this, several drugs have already been discovered by this approach, such as Saquinavir (antiviral), Zanamivir (antiviral), Norfloxacin (antimicrobial), Dorzolamide (antiglaucoma), and Oxymorphone (narcotic analgesic) (in clinical trials) [13].

CA-clan papain-like cysteine proteases (CP) represent a group of targets present in several parasites associated with NTDs that have been exhaustively explored in various virtual screening studies. These enzymes are proteases that irreversibly hydrolyze nucleophilic attack-mediated peptide bonds that generate a tetrahedral intermediate. Furthermore, cysteine proteases are present in different life forms of various NTD-mediating parasites, participating in diverse biological processes [19 - 21]. Thus, they constitute potential targets for drug design and development of antiparasitic compounds, such as the promising vinyl sulfone K777 (Fig. 1), in the preclinical stage against Chagas disease, for example [19, 22, 23].




Fig. (1). Most promising vinyl sulfone (K777) found in the literature.

This chapter summarizes a compilation of studies involving the application of molecular modeling approaches for developing new cysteine protease inhibitors. It will focus on the development of inhibitors against cruzain (*Trypanosoma cruzi*), falcipain (*Plasmodium falciparum*), SmHDAC8 (*Schistosoma mansoni*), nsP2 (Chikungunya virus), cathepsin-S, -K, -B, and -L (human), 3C<sup>pro</sup> (Enterovirus 71), 3CL<sup>pro</sup> (Coronavirus), and caspase-1 and 3 (human) by using virtual screening techniques.

## VIRTUAL SCREENING IN DRUG DEVELOPMENT

The discovery of new drugs is a complex and time-consuming process that requires a high degree of knowledge in different areas of science and has faced many changes and challenges in recent decades [24]. Recently, the development of drug has included virtual screening methods in which molecules do not

**CHAPTER 3****Application of Systems Biology Methods in Understanding the Molecular Mechanism of Signalling Pathways in the Eukaryotic System****Aditya Rao S.J.<sup>1</sup> and M. Paramesha<sup>1,2,\*</sup>**<sup>1</sup> *Dept. of Plant Cell Biotechnology, CSIR-Central Food Technological Research Institute, Mysuru, India*<sup>2</sup> *Dept. of Food Technology, Shivagangotri, Davangere University, Davangere, Karnataka, India*

**Abstract:** A signalling pathway is a cascade of reactions carried out together by a group of molecules in a system to bring out the metabolic functions starting with cell division to cell death. When signalling pathways interact with one another, they form networks, which allow cellular responses to be coordinated, often by combinatorial signalling events. Any abnormal change affecting the activation or deactivation of such signalling events leads to the abnormal physiological cellular functions. The understanding of the molecular mechanism of signalling pathways is beneficial to understand the pathological scenery and treatment. Recent advancements in computational methods have given a new insight to understand the molecular mechanism involved in signalling pathways. The use of systemic and computational tools is crucial in systems biology as the complexity of the biological system is more, a vast amount of data is being generated and the scattered pieces of information has to be integrated into a meaningful order. The present chapter deals with the utilization of systems biology tools, and data mining techniques to understand the molecular mechanism of 'Wnt signalling pathway; an intercellular pathway which regulates critical aspects of cell fate determination, cell migration, cell polarity, neural patterning and organogenesis during embryonic development', with the integrated software platforms, which could help to address the future research problems in biology and medicine.

**Keywords:** Axin, Cancer,  $\beta$ -catenin, GSK-3 $\beta$ , Network analysis, Pathway prediction, Systems biology, Tankyrase, Therapeutics, Wnt signalling pathway, Wnt ligands, Wnt protein.

---

\* **Corresponding author Dr. Paramesha M:** Associate Professor, Department of Food Technology, Shivagangotri, Davangere University, Davangere, Karnataka, India; Tel: +919481535168; E-mails: parameshbt@gmail.com; paramesham8@davangereuniversity.ac.in

## INTRODUCTION

### Intercellular Signalling Pathways

Cells communicate through cellular pathways, which play a significant role in their development. These pathways can be considered as ‘control knobs’ as they not only induce or block cellular differentiation during growth [1] but also control cellular behaviour [2, 3]. This can be exploited for biomedical applications in regenerative medicine [4, 5] as well as in providing valid drug targets [6, 7]. The intercellular signalling pathways have attracted many researchers due to their prevalent and diverse roles. The conservation of these intercellular signalling pathways across different species has made them the best-studied systems in biology in recent times. For many intercellular pathways, their association with ligands, receptors, intracellular effectors, transcription factors, and modulators have been identified, and their interactions have also been characterized. However, with the existing knowledge on the behaviour of intercellular pathways, some of the most basic operational questions still remained unanswered. These answers help in understanding specific molecular interactions, including how cell receives, processes and treats extracellular signals within the cell.

### WHAT IS WNT?

The term Wnt stands for ‘wingless- related integration site’ which is derived from two words, namely ‘wingless’ and ‘int’. The sequencing studies in *Drosophila* revealed the homogeneity of its wingless gene with oncogene int-1. Hence int/wingless family was considered as Wnt family. Wnts are involved in many crucial cellular processes like regulating the cell growth, motility, differentiation during embryonic development, controlling cell proliferation and cell fate apart from activating diverse signalling cascades. The degradation rate of  $\beta$ -catenin, a secondary messenger that acts as a transcriptional co-regulator in cell proliferation, is controlled by Wnt signalling.  $\beta$ -catenin will be degraded by multiple protein complexes when the Wnt pathway is inactive. This protein complex can be inactivated by the activity of receptor-targeted inhibitors, which results in accumulation of  $\beta$ -catenin [8]. This suggests that the  $\beta$ -catenin level can be externally controlled by the involvement of ligands, thus controlling Wnt signalling. The concentration of  $\beta$ -catenin is found to be different from cell to cell due to the variations in biochemical pathways and their fold-change resulted by the stimulation from external ligand but found to be uniform across cells [9]. This adaptive response of cells to external stimuli to produce  $\beta$ -catenin is controlled by Wnt genes [9]. Thus, it is possible to control the response of Wnt signals in turn controlling the cell fate decision by controlling the level of stimulation [10].

## Types of Wnt Signalling Pathway

Based on the involvement of  $\beta$ -catenin, the Wnt pathway can be classified as follows:

1. Canonical Signalling Pathway
  - $\beta$ -catenin dependent
  - $\beta$ -catenin independent
2. Non-Canonical Signalling Pathway

## CANONICAL PATHWAY

### $\beta$ -Catenin Dependent Canonical Pathway

The canonical pathway is also known as Wnt/ $\beta$ -catenin dependent signalling pathway [11] and also considered as a first identified pathway, which involved in the vital process such as cell proliferation, ribosome biogenesis, and inhibition of apoptosis [12]. Maintenance of intracellular  $\beta$ -catenin is associated with the canonical Wnt pathways. The activation of the canonical pathway starts with the binding of Wnt ligand to its receptor (Fig. 1). The ' $\beta$ -catenin destruction complex' is composed of scaffold protein Axin, glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ), Casein Kinase-1 $\alpha$  (CK-1 $\alpha$ ), and the tumour suppressor adenomatous polyposis coli (APC) [13, 14]. This destruction complex exhibits the sequential phosphorylation by the CK-1 $\alpha$  and GSK-3 $\beta$  enzymes present in the destruction complex and is targeted by ubiquitination and proteasome degradation [12, 15 - 17]. Thus, it controls the concentration of  $\beta$ -catenin accumulation in the cytoplasm and, in result, it will impede the signalling activity of Wnt/  $\beta$ -catenin in the nucleus. Meanwhile, in the absence of  $\beta$ -catenin, transcriptional repressor Groucho binds to TCF (T-cell factor)/LEF (lymphoid enhancer factor), which inhibits the transcription of genes. Stabilization of  $\beta$ -catenin is initiated by Wnt protein, when it binds to the transmembrane receptor Fz (Frizzled) and the co-receptor LRP5/6 (low-density lipoprotein receptor-related protein-5/6) [18, 19]. The Wnt protein, Fz and LRP5/6, forms receptor complex, which facilitates the Dishevelled (Dvl) protein to the membrane, which leads to the formation of Signalosome [12]. The Signalosome provides the platform to the " $\beta$ -catenin destruction complex," resulting in disassembly of " $\beta$ -catenin destruction complex" initiated by CK-1 $\alpha$ , which phosphorylates LRP5/6. As a result of this, cytoplasm abundant of  $\beta$ -catenin translocates to the nucleus, which ultimately displaces the transcriptional repressor Groucho and binds to TCF (T-cell factor)/ LEF (lymphoid enhancer factor) and triggers the expression of target genes [12, 17, 20 - 22].

# Implementation of the Molecular Electrostatic Potential over GPUs: Large Systems as Main Target

J. César Cruz, Ponciano García-Gutierrez, Rafael A. Zubillaga, Rubicelia Vargas and Jorge Garza\*

*Departamento de Química, División de Ciencias Básicas e Ingeniería, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México*

**Abstract:** The molecular electrostatic potential (MEP) is a useful tool to design and develop drugs. However, the evaluation of this property using quantum chemistry methods presents a challenge for molecules of medium or large size since this is computationally expensive. In this chapter, we showed two implementations of this property over graphics processing units (GPU). In the first instance, we discussed some details that must be considered when GPUs are involved in high-performance computing. After this step, the algorithms considered to evaluate MEP over GPUs are exposed to observe the main differences between a method with minimal approximations and another one where usual approximations are implemented in many quantum chemistry codes. The benefits provided by these graphics cards are evidenced when our implementations are applied over molecules of considerable size like those found in protein-ligand complexes, where usually the electrostatic potential is modeled by a set of point charges.

**Keywords:** Cuda-C, GPUs, Molecular Electrostatic Potential, Multipolar Expansion, Proteins.

## INTRODUCTION

Electrostatic interactions are crucial to form non-covalent interactions in biological systems where many biomacromolecules contain electrical charges in a great variety of fragments built with small charged molecules and monoatomic ions. As an example, we can mention globular proteins, which are polyelectrolytes with ionized amino acid residues like Asp and Glu with a negative charge, and Lys and Arg with a positive charge; these four types of

\* **Corresponding author Jorge Garza:** Departamento de Química, División de Ciencias Básicas e Ingeniería, Universidad Autónoma Metropolitana-Iztapalapa, San Rafael Atlixco 186, Col. Vicentina. Iztapalapa. C. P. 09340, Ciudad de México, México; Tel: 525558044600; E-mail: jgo@xanum.uam.mx

residues represent about a quarter of all residues in an average protein [1]. In general, the biological activity of a protein shows up by interacting selectively with another biomolecule, large or small, and the electrostatic contribution to the binding energy is crucial in many cases [2, 3]. To visualize better the tendency of favorable electrostatic interactions between two molecules, instead of using the representation of positive and negative surface charges it is more accurate to display the molecular electrostatic potential (MEP), since even in proteins with a small net charge, patterns of positive and negative electrostatic potential are over the molecular surface [1]. The complementarity of the MEP between different fragments dictates the formation of a complex, and sometimes such a complementarity is more important than a different sign of their net charges [4]. Besides, the charged state of some polypeptides is modulated by post-translational modifications like phosphorylation, in response to extracellular signals, changing the MEP locally and creating new binding epitopes for specific targets. Many of the mutations that lead to cancer involve ionizable residues [4]. Nucleic acids are among the strongest natural polyelectrolytes, which contain a phosphate group ( $\text{PO}_4^-$ ) for each base in their sequence so they can interact favorably with molecules displaying surfaces of positive MEP (see Fig. 3 of Honig and Nicholls [4]). Phospholipid membranes also have strong electrostatic interactions with proteins and other biomolecules. Therefore, the computation of the MEP is desirable for these cases.

Evaluation of the MEP is not an easy task if this is obtained from its definition [5, 6]

$$\Phi(\mathbf{r}_2) = \sum_A \frac{Z_A}{|\mathbf{r}_2 - \mathbf{R}_A|} - \int d\mathbf{r}_1 \frac{\rho(\mathbf{r}_1)}{|\mathbf{r}_1 - \mathbf{r}_2|}, \quad (1)$$

where precisely the charges in the system are involved in computing this property. In this case,  $Z_A$  represents the nuclear charge of each atom in the system, and the electron density is represented by  $\rho(\mathbf{r})$ . From definition (1), one can deduce that there are sites in a molecule where nuclei command and, therefore  $\phi(\mathbf{r})$  is positive, and regions where the electron density rules and consequently  $\phi(\mathbf{r})$  is negative; this characteristic has been widely used in quantum chemistry applications [7 - 11]. For molecular systems, we need the electron density from quantum chemistry methods, or from experimental information, to use equation (1). In this chapter, we will deal only with theoretical approaches related to the electronic structure of atoms and molecules. Thus, the evaluation of the MEP could be computationally expensive and some times prohibitive for systems of considerable size. This contribution aims to discuss two algorithms to obtain the MEP over graphics processing units (GPU). In our group we have developed

some strategies to implement grid-based methods over GPUs to determine quantum chemistry scalar and vector fields like the electron density and derivatives of it. As we can see from equation (1) this property is directly involved with the MEP, and for that reason, we think that an analysis of its implementation over GPUs is appropriate currently, since this hardware has high availability.

## GRAPHICS PROCESSING UNITS IN QUANTUM CHEMISTRY

Graphics processing units have gained a relevant role in the high-performance computing, particularly in quantum chemistry [12 - 19] or in computational modeling based on molecular dynamics [20 - 23]. The number of threads and the memory involved in a GPU of the last generation are desirable to developers of parallel computing applications. In our group, we have reported the evaluation of scalar and vector fields defined in quantum chemistry, over grids with the use of GPUs. In specific, we have developed the graphics processing units for atoms and molecules (GPUAM) [24, 25] code with the primary purpose of the development of an application where personal computers with an installed GPU can be used for demanding computational tasks. This code uses WFN or WFX files as input data, which are ASCII files, and they can be used in any computational system. These files are obtained from programs like GAMESS [12], Gaussian [13], or NWChem [14]. Besides, the Molden2AIM [26] code allows us to use other formats to convert the corresponding files in WFN or WFX formats, which contain nuclei coordinates, exponents of the basis set, and the coefficients  $\{c_i\}$  that give the best representation of Hartree-Fock or Kohn-Sham orbitals in terms of a basis set, even correlated methods can be used if the coefficients of natural orbitals are in these formats. In this chapter, we do use Terachem [15, 16, 18], which has been designed from scratch to be executed on GPUs and the files delivered by this code are transformed to WFX format by using Molden2AIM. With wfn or wfx files, the GPUAM evaluates a scalar or vector field, assigning one thread of the GPU to one point of the grid. At the end of this process, GPUAM writes the final results in permanent memory through files with cube format, which is a standard extension introduced by Gaussian, Inc. This procedure is sketched in Fig. (1).




Fig. (1). Procedure to obtain a scalar or vector field defined in quantum chemistry using GPUAM.

In GPUAM, the grid is distributed over a GPU, or over the GPUs defined by a



# Molecular Electron Density Theory: A New Theoretical Outlook on Organic Chemistry

Luis R. Domingo<sup>1,\*</sup> and Nivedita Acharjee<sup>2</sup>

<sup>1</sup> Department of Organic Chemistry, University of Valencia, Dr. Moliner 50, Burjassot, E-46100, Valencia, Spain

<sup>2</sup> Department of Chemistry, Durgapur Government College, West Bengal, India

**Abstract:** Organic Chemistry has evolved continuously as the backbone for the sustainability of different disciplines such as medicinal chemistry, chemical biology, biochemistry, biotechnology, material science, polymers, and nanotechnology. The beauty of organic reactions lies in their unique structural framework, reactivity, and selectivity, interesting stuff for molecular modelling research. However, theoretical interpretations of organic reactions have not been able to keep pace with the ever-increasing efficiency of computational chemistry software along the last two decades. This is probably due to the popular use of the Frontier Molecular Orbital (FMO) theory to study the course of organic reactions during the last 40 years, in spite of its failure and criticism in several cases. In 2016, Domingo proposed a new theory, called “**Molecular Electron Density Theory (MEDT)**” to study molecular reactivity of organic reactions, which is backed up by the use of quantum chemical tools. This theory proposes the decisive role of electron density changes in the reactivity of organic molecules, being opposed to FMO concepts. MEDT has been successfully applied to rationalize the experimental outcome of several Diels-Alder reactions, sigmatropic rearrangements, electrocyclic reactions, and [3+2] cycloaddition reactions. MEDT covers the detailed analysis of Conceptual DFT (CDFT) indices, exploration of the Potential Energy Surface (PES), calculation of the global electron density transfer (GEDT), topological analysis of the Electron Localization Function (ELF) and Quantum Theory of Atoms in Molecules (QTAIM), and Non-Covalent Interactions (NCI) with the aid of molecular modelling software. MEDT correlates the changes in electron density along a reaction path with the activation energies and establishes the polar character associated with the reorganization of the molecular mechanism to reach a meaningful insight into the reactivity of organic molecules. MEDT can be applied to study the mechanism, reactivities and selectivities of organic reactions, particularly those showing chemo-, regio-, and stereoselectivities in the synthesis of biologically active products. This chapter aims to provide a detailed description of the basic theoretical concepts covered by MEDT to design a precise computational model of an organic reaction. Some applications of MEDT have also been illustrated in the concluding section for ready reference.

\* **Corresponding author Luis R. Domingo:** Department of Organic Chemistry, University of Valencia, Dr. Moliner 50, Burjassot, E-46100 Valencia, Spain; E-mail: domingo@utopia.uv.es

**Keywords:** Bond Critical Points, Bonding Evolution Theory, Conceptual DFT, Electron Density, Topology, Electron Localization Function, Global Electron Density Transfer, Intrinsic Reaction Coordinate, Laplacian, Molecular Electron Density Theory, Non-Covalent Interactions, Potential Energy Surface, Quantum Theory of Atoms in Molecules, Transition States Structures.

## INTRODUCTION

Having evolved as a highly creative discipline of science, Organic Chemistry is widely applied in medicine [1, 2], nanotechnology [3], polymers [4], industrial synthesis [5], biochemistry [6], biotechnology [7], and cosmetics [8]. "structural beauty and wide applicability of organic molecules come from their" chemical framework, which defines their unique reactivity. Thus, the interpretation of organic reactivity is a tough challenge, crossing the scientific boundaries of physical, chemical, and mathematical theories. The ever-increasing speed and capabilities of computational resources have significantly reduced the time required to calculate mathematical functions, which has provided the mathematical solution for physical and chemical theories applied to study the energetics and reactivity of molecular systems.

All chemical changes are accompanied by the absorption or release of heat, and this intimate connection of matter and energy has been in the focus of studies to understand the course of a chemical reaction. The first link between the experimental energy barrier of a chemical reaction and the theoretical concept of "transition state" was put forward in the "Transition State Theory (TST)" [9]. The chemical changes are associated with changes in the bonding framework of a molecular system, which causes energy transformations along a reaction path. Thus, the interplay of theory and experiment is well understood when exploring the sequence of bonding changes along a chemical reaction. Understanding "chemical bonding" in its deepest aspect and the electronic structure of a molecule is, therefore, crucial to analyze the energetics of a chemical reaction.

The Lewis concept of chemical bonding [10] laid the foundation for the advent of two new theories, popularly used in Organic Chemistry, namely the Valence Bond Theory [11 - 13] (VBT) and Molecular Orbital Theory [14] (MOT). VBT and MOT are two approximate methods for the solution of Schrödinger's equation [15]. Within VBT, organic reactivity is explained by hybridisation, resonance, inductive effect, and other relevant concepts. MOT evolved as a unique concept proposing the movement of electrons along molecular orbitals (MOs) in a molecule. MOT considers the Born Oppenheimer's approximation [16], which considers a molecule as an entity and each electron moves under the influence of the potential field of all the nuclei, rather than being centered on one nucleus.

MOs are constructed by the linear combination of atomic orbitals [17] (LCAO) from each atom of the molecule. Huckel's Molecular Orbital Theory [18 - 20] is a popular approach used in Organic Chemistry, where MOs are built only from valence atomic orbitals. This concept was presented as a novel treatment of chemical reactivity and named Frontier Molecular Orbital (FMO) Theory by Fukui *et al.* in 1952 [21]. Many years later, the FMO theory gained serious interest, when it was applied by Woodward and Hoffmann [22] in 1965 to interpret the electrocyclic ring opening of cyclobutenes. The FMO theory thus started gaining ground as a reliable theoretical approach for the interpretation of organic reactions, particularly cycloaddition reactions [23, 24]. The FMO concept was advocated in the 1960-70s by Woodward and Hoffmann [25], Fukui [26], and Pearson [27], which led to the use of FMOs for the interpretation of cycloadditions by Houk [28] in 1972-73. Failures of the FMO theory were also recognized [23], but such cases were labelled as uncommon, subject to special circumstances in the 1970s. The general failure of the FMO theory to interpret electrophilic aromatic substitutions,  $S_N2$  reactions, and so-called "pericyclic reactions" was critically reviewed and questioned by M.J.S. Dewar [29] in 1989. The author pointed out two reasons for the popularity and general acceptance of the FMO theory in Organic Chemistry: (I) the FMO theory is claimed as the only alternative for the interpretation of "pericyclic reactions", which cannot be explained by any other concept [23]; (II) by using the FMO theory, calculations can be performed swiftly, and the reactivity of organic reactions can be interpreted without using any concept of Organic Chemistry, which naturally, led to the popularity of the FMO concept. Thus, although the failures of the FMO theory were recognized in many cases, it is applied as an easy approach reactivity to understand organic reactions, particularly "pericyclic reactions".

The growth of computational chemistry [30] in the 20<sup>th</sup> and 21<sup>st</sup> century has made it possible to explore the potential energy surface (PES) [31] defined under the TST [9]. Consequently, reactants, products, transition state structures (TSs) and intermediates can be characterized on the PES. Now, a proper quantum chemical approach is required to obtain the electronic energies of these stationary states. As a consequence, a new quantum mechanical modelling method based on the Hohenberg and Kohn theorem [32], called the Density Functional Theory (DFT) [33] was proposed using Kohn-Sham equations [34]. DFT expresses the ground state energy of a non-degenerated  $N$  electron system as a function of electron density ( $\rho$ ). DFT has proved to be a major breakthrough in computational chemistry due to its accurate predictions of energy and reactivity, unlike *ab initio* calculations [35].

Electronic energies of the stationary points located on the PES of a reaction can be obtained precisely by DFT calculations, but a proper theoretical approach is

# Frontier Molecular Orbital Approach to the Cycloaddition Reactions

Anjandeep Kaur\*

Department of Chemistry, Government Mohindra College Patiala, Punjab, 147001, India

**Abstract:** The frontier molecular orbital (FMO) theory has provided a powerful model for the qualitative understanding of reactivity and regioselectivity of the Cycloaddition reactions, based on the electronic properties of isolated reactants. The 1,3-dipolar cycloaddition reactions are explicable by the frontier molecular orbital approach, which is based on the assumption that bonds are formed by a flow of electrons from the highest occupied molecular orbital (HOMO) of one reactant to the lowest unoccupied molecular orbital (LUMO) of another. But the tricky part here was to decide which molecule supplied the HOMO and which supplied the LUMO. Furthermore, the computational chemistry techniques like  $\text{HOMO}_{\text{dipole}}\text{-LUMO}_{\text{dipolarophile}}/\text{HOMO}_{\text{dipolarophile}}\text{-LUMO}_{\text{dipole}}$  energy gaps, electronic chemical potentials ( $\mu$ ), electrophilicity indices ( $\omega$ ) and the charge capacities ( $\Delta N_{\text{max}}$ ) are useful in indicating whether the reactions are under normal or inverse electron demand conditions. Also, the relative kinetics of cycloaddition reactions can be rationalized by utilizing  $\text{HOMO}_{\text{dipole}}\text{-LUMO}_{\text{dipolarophile}}$  energy gaps and  $\Delta N_{\text{max}}$ , from which it was found that increasing electron-withdrawing power of the dipolarophile substituents, the energy gap decreases and, thus, reactions with the same dipole became faster in Normal electron demand cycloadditions, while the reverse occurs in case of inverse electron demand conditions.

**Keywords:** Cycloaddition, Chemical Potential, Charge Capacity, Diastereoselectivity, Dipolarophile, Electrophilicity, Enantioselectivity, Inverse Electron Demand Reactions, Normal Electron Demand Reactions, Regioselectivity, Stereochemistry.

## INTRODUCTION


The language of chemistry is replete with orbitals, whether they be hybrid orbitals (in valence-bond models) or linear combination of atomic orbitals (in molecular orbital models). The power of the orbital concept cannot be avoided: almost everything in chemistry can be described, at a qualitative level by the appropriate use of an orbital model. The ‘Orbital’ concept, which was established by many

\* Corresponding author Dr. Anjandeep Kaur: Department of Chemistry, Government Mohindra College Patiala, Punjab, 147001, India, E-mail: kauranjandeep@gmail.com

scientists, was initially used to construct the wave function of molecules through which molecular properties were usually interpreted [1]. In 1950's, Fukui developed Frontier molecular orbital theory on the basis of which he proposed that the pair of  $\pi$ -electrons occupying the highest orbital, which is referred to as frontier electrons, plays a decisive role in chemical activation of molecules. Instead of thinking about the total electron density, he focused on two particular orbitals, which act as an essential part in a wide range of chemical reactions and referred these orbitals as Highest occupied molecular orbitals (HOMO) and Lowest unoccupied molecular orbitals (LUMO) [2 - 4]. Based upon this FMO approach, he provided a simple and clear picture of theoretical interpretation of many reactions and 'The Overlap and Orientation' principle of Mulliken for the formation of molecular complexes [5, 6]. The utility of Fukui's study was further broadened by the role of symmetry orbitals pointed by Diels and Alder in the cycloaddition reactions. Based upon the symmetry of molecular orbitals, Woodward and Hoffmann proposed a principle called 'The conservation of orbital symmetry' to explain stereochemistry in pericyclic reactions [7 - 9]. The century-old class [10 - 13] of 1,3-dipolar cycloaddition (1,3-DC) is a well-studied field of organic chemistry. These reactions have a wide application in the synthesis of many pharmaceutically important compounds and intermediates [14, 15].

In the beginning, the concept of 1,3-dipolar cycloadditions was given by Smith in 1938 [16], but the generalization given by Huisgen, in 1960, made it widely applicable [17]. The research in the field of 1,3-dipolar cycloaddition reactions is utilized in almost every area of chemistry, from material chemistry [18] to drug discovery [19], indicating its diversity. 1,3-Dipolar cycloaddition is considered as an important reaction in synthetic organic chemistry where the two organic molecules *i.e.* a 1,3-dipole **I** and a dipolarophile **II**, join to give a five-membered heterocycle **III** (Scheme 1). A number of simple and complex heterocycles of immense importance for the industrial and academic world can be prepared from simple and easily accessible molecules by 1,3-dipolar cycloaddition reaction. These reactions are commonly used as a key step in several organic syntheses [20].

As the control of stereochemistry is the major challenge in cycloaddition reactions, therefore, in recent years, such reactions have entered a new stage of development. Nowadays, controlling the regioselectivity, enantioselectivity, and diastereoselectivity of the 1,3-dipolar cycloaddition reactions is the main challenge. Their stereochemistry can be brought under control by either controlling the reaction by a metal complex acting as a catalyst or by selecting the appropriate substrate [21 - 23].



**Scheme 1.** Basic schematic representation of 1,3-dipolar cycloaddition reactions.

### 1,3-DIPOLE/YLIDE

Curtius was considered as a pioneer in the history of 1,3-dipoles with the discovery of diazoacetic ester, in 1883 [24]. The 1,3-dipole or an ylide has a positive and a negative charge spread over three atoms and possesses  $4\pi$ -electrons [25]. Generally, the elements of groups 14, 15, and 16 are included in 1,3-dipoles among which nitrogen, carbon, and oxygen are the predominant ones and due to this limitation on the central atom of the dipole, a limited number of structures can be made by combination and permutations of these three atoms.

The elements of the higher row like sulfur and phosphorus, can also be included in 1,3-dipoles, but only a few cycloaddition reactions involving such types of dipoles have been published. The ylides or 1,3-dipoles can be represented by two octet-structures and two sextet structures. In the case of octet structure, the positive charge is present on the central atom while the two terminal atoms have a negative charge distributed over them. In sextet-structure, two among the four  $\pi$ -electrons are localized at the central atom. This structure explains the ambivalence of the 1,3-dipole but contributes little to resonance hybrid's electron distribution. The ambivalent nature of 1,3-dipole plays a major role in comprehending the regiochemistry, reactivity, and mechanism of 1,3-dipolar cycloadditions.

### Classification of 1,3-Dipoles

1,3-Dipoles were categorized by Huisgen into two categories *i.e.* allyl anion type and propargyl/allenyl anion type 1,3-dipoles. They are also referred to as  $sp^2$  and  $sp$  hybridized 1,3-dipoles, respectively.

#### *Allyl Anion Type 1,3-Dipoles*

The allyl anion type 1,3-dipoles are bent in nature and have four  $\pi$ -electrons in parallel to three  $p$ -orbitals, which are perpendicular to the plane of the dipole

## SUBJECT INDEX

**A**

Activation 68, 111, 113, 117, 118, 129, 206  
 enthalpy 206  
 Adenomatous polyposis coli (APC) 113, 120  
 tumour suppressor 113  
 ADME properties and binding 36  
 ADMET 17, 18, 31, 32  
 analysis 31, 32  
 properties 17, 18, 32  
 Allergic asthma 95  
 Alzheimer's disease 98, 120  
 Apoptosis 98, 113, 119  
 Arthritis 93  
 ASINEX database 36  
 Asinex platinum 82  
 Atherosclerosis 94  
 Atomic spin densities (ASDs) 185, 186, 188  
 Azomethine imine cycloaddition reactions 241

**B**

Bader's quantum theory 200  
 Bank of molecules of the Amazon (BMA) 38,  
 39  
 Bayesian theory 125  
 BIA evaluation software 43  
 Binding site 9, 11, 32, 83, 89, 100, 128  
 analysis 32  
 internal protein 9  
 Binding 6, 40  
 strength 40  
 thermodynamics 6  
 Bond 65, 69, 92, 199, 202, 228, 233, 234  
 acidic peptide 92  
 attack-mediated peptide 65  
 reactive peptide 69  
 triple 233  
 Bonding evolution theory (BET) 175, 196,  
 198, 206, 207  
 Bonding pattern consistency 36  
 Born-Oppenheimer approximation 175, 193  
 Brainstem encephalitis 96

Burgi-Dunitz trajectory 185

**C**

Cambridge structural database (CSD) 18  
 cAMP response element-binding protein-1  
 118  
 Cancer 37, 93, 101, 111, 118, 120, 123, 127,  
 132, 150  
 breast 127  
 gastrointestinal 127  
 liver 37  
 Canonical pathway 113, 114, 120  
 conservative 114  
 independent 114  
 Canonical signalling pathway 113  
 Carnosic acid 131  
 Caspase-1 65, 98  
 inhibitors 98  
 Chagas disease 65, 68, 70  
 Charge 26, 27, 195, 200, 228, 244, 247  
 capacities 228, 244, 247  
 density 26, 27, 200  
 distribution 159, 160  
 transfer (CT) 27, 195, 244  
 Chembridge 43, 47, 83  
 and Asnex databases 83  
 libraries 43, 47  
 Chemical  
 behaviour 178  
 changes 175  
 composition 41  
 Chemical hardness 91, 178, 179, 181, 243,  
 244  
 expressed 178  
 concept 244  
 structures of praziquantel and oxamniquine  
 drugs 91  
 Chemoselective reaction 217  
 Chikungunya 63, 65, 88  
 fever 88  
 virus 63, 65, 88  
 Complete chemo- and regioselective reaction  
 215

- Complex 122, 123  
  biological interactions 122  
  disease mechanism 122, 123
- Computational 1, 2, 3, 25, 28, 35, 38, 74, 101, 111, 122, 132, 154, 165, 175, 177, 194  
  chemistry software 174  
  chemistry tools 1  
  drug design approaches 25  
  drug development method 3  
  effort 154, 165  
  methods 28, 35, 38, 101, 111, 122, 132, 194  
  quantum calculations (CQC) 177  
  resources 175  
  screening 2  
  software 177
- Computer aided drug discovery (CADD) 2, 3, 26, 28, 29, 34, 37, 38, 41, 43, 48, 49, 64, 65
- Conceptual 174, 175, 177, 178  
  density functional theory 177  
  DFT (CDFT) 174, 175, 177, 178
- Coronavirus 1, 3, 28, 41, 43, 63, 65, 96, 97  
  replicase polyproteins 97
- Covalent docking method 96
- Covalent inhibitors 69, 71, 96  
  potential 71
- Cruzain 63, 65, 68, 70, 71, 72, 73, 75, 76, 77, 78  
  enzyme 71, 73  
  inhibitors 72, 73, 78
- Cryo-electron microscopy 22
- Cyclic nitrene, reaction of 213
- Cycloaddition 176, 177, 228, 234, 235, 237, 238, 239, 241, 246, 247  
  of carbonyl ylide 238  
  regioselective 238  
  reaction of diazomethane 238
- Cysteine proteases (CP) 63, 64, 65, 67, 68, 69, 70, 96, 97, 98, 200, 201, 202, 204  
  catalytic mechanism of 69  
  parasite 63
- Cysteine-rich domains (CRD) 128
- Cytokine production 98
- Cytopathic inhibition assay 36
- D**
- Databases 3, 11, 33, 35, 40, 44, 47, 66, 76, 81, 82, 126
- organic molecule 81  
  virtual 66
- de novo* design 11, 12  
  patterns 12
- de novo* drug design 12  
  based 12
- Density 69, 165, 176, 213, 217, 235  
  electronic 165  
  functional theory (DFT) 69, 176, 203, 213, 217, 235  
  gradient, reduced 203  
  lone pair 213
- Desai's studies 81
- DFT calculations 176, 194
- Diabetes mellites 123
- Dipolarophiles 228, 233, 237, 239, 240, 241, 243, 244, 245, 246, 247  
  electron-deficient 245  
  electron-rich 241, 245  
  substituted 243  
  tetrasubstituted 233
- Dipole interactions 24
- Direct acting antivirals (DAAs) 40
- Diseases 2, 4, 5, 18, 19, 22, 28, 33, 37, 64, 68, 78, 90, 91, 93, 120, 121, 123, 124  
  cardiovascular 93, 121  
  complex 19, 124  
  complex human 123, 124  
  coronary artery 121  
  fatal 28  
  fatty liver 121  
  global 64  
  oral 121  
  parasitic 78, 90
- Dishevelled protein 127
- Docking 9, 10, 35  
  blind 35  
  efficient ligand-protein 9  
  protein-ligand 9, 10
- Docking analysis 31, 32, 35, 36, 37, 40, 47, 48  
  molecular 35
- Docking  
  energies 40  
  experiments 39, 40  
  scores 39, 74
- Double bond 69, 195  
  regions 195  
  replacement 69
- Drug design 5, 19, 65, 70, 86, 88  
  multi target 19



trypanocidal 70  
Drugs 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 17,  
19, 25, 26, 28, 29, 32, 33, 38, 65, 75, 78,  
101  
active 2, 38  
aided 7, 8, 11, 19, 25, 29, 33  
antifungal 32  
antimalarial 78  
antiparkinson 75  
anti-protozoal 19  
computational 17  
new anti-inflammatory 98  
novel predicted 31  
relevant 35  
single target 19  
Drug target common (DTC) 44  
Dynamics 114, 122, 126  
cytoskeleton 114

## E

Ebola 1, 2, 3, 19, 28, 30  
and Zika virus infection 19  
haemorrhagic fever 28  
Ebola virus 26, 28, 29, 31, 32  
disease 28, 29  
genome 29  
nucleoprotein 29, 31  
proteins 31  
Electron density 26, 27, 150, 151, 154, 165,  
167, 177, 178, 179, 190, 195, 198, 199,  
200, 202, 203, 204, 205, 208, 209  
accumulation of 202, 204  
exchange 178, 179  
non-bonding 209  
sign of Laplacian of 202, 203  
topological analysis of 205, 208  
Electron density 181, 195, 196, 198, 200, 217  
decays 200  
flux 181, 195, 196, 200  
transfer 196, 198, 217  
transfer complexes (EDTCs) 196  
Electron-donating groups (EDG) 239, 240,  
241, 245  
Electronegativity equalisation principle 181  
Electron localization function (ELF) 174, 175,  
189, 190, 191, 196, 207, 208, 217  
Electrophile LUMO interactions 185  
Electrophilic 176, 184, 185, 187, 188, 215,  
238, 241

activation 188, 215  
aromatic substitutions 176  
attack of acrolein 187  
Electrophilicity 179, 180, 181, 182, 187, 188,  
228, 245  
index 179, 180, 187, 245  
indices, computed 180  
scales 180  
ELF 190, 191, 196, 197, 198, 199, 204, 208  
analysis 204  
basin populations 191  
gradient fields 190  
localization domains 192  
topological analysis 196, 198, 208  
topological phases for polar 197  
valence basin populations 199  
Endolysosomal biogenesis 116  
Endothelial dysfunction 121  
Energy 24, 27, 48, 164, 175, 176, 177, 178,  
179, 193, 206, 207, 235, 239, 243, 245  
calculations 48  
electronic 176, 193  
molecular relaxation 206, 207  
pathway 235  
stabilisation 179  
stabilization 243  
transformation 175, 193  
vibrational 24  
Exo-endo isomeric ratio 235

## F

Familial adenomatous polyposis (FAP) 120  
FAP gene 120  
Fibrosis 93, 121  
cystic 93  
pulmonary 121  
Fluctuations 23, 39  
dynamic structural 23  
Fluorescence resonance energy transfer  
(FRET) 47  
FMO theory 176, 177, 217, 237  
in organic chemistry 176  
Focal dermal hypoplasia 121  
Focused cysteine protease inhibitor (FCPI) 82  
Foldamers 12  
abiotic 12  
Force field 21, 24, 25, 27  
generalized molecular mechanics 24  
proper molecular mechanics 21

Fragment molecular orbital method 27  
Frontier molecular orbital (FMOs) 27, 28,  
174, 176, 228, 245  
Fukui functions 183, 184, 186  
Fukui's study 229  
Fumaric acid 235  
Functions 4, 22, 28, 29, 31, 33, 39, 47, 63, 67,  
74, 88, 98, 111, 117, 120, 122, 124, 153,  
156, 157, 159, 164, 165, 167, 175, 229  
abnormal physiological cellular 111  
catalytic 67  
cognitive 120  
complex cellular 122  
enzymatic 88  
extra precision score 74  
general catabolic 63  
liver 28  
mathematical 175  
metabolic 111  
neuronal 98  
physiological 67  
primitive 164, 165, 167  
regulatory 67  
viral proteases 47  
wave 4, 229

**G**

Gastrointestinal tract disorders 70  
Gaussian 39, 45, 153, 154, 159, 161  
distributions, spherical 159  
functions 159, 161  
product rule 159  
software 39, 45  
type functions (GTFs) 153, 154  
Gene-based data analysis methods 125  
Genes 2, 34, 98, 113, 118, 120, 122, 124, 126  
functional 122  
validated protein-encoding 126  
Genetic polymorphism 121  
Genome 123, 124, 126  
analysis 126  
-wide association studies (GWAS) 123,  
124  
large-scale 123, 124  
Genuity-pathway-analysis 126  
Global 174, 175, 195, 196, 206, 243  
electron density transfer (GEDT) 174, 175,  
195, 196, 206  
electrophilicity power measures 243

Glycoproteins 29, 32, 37, 42, 118  
extracellular secreted 118  
targeted 32  
Growth 19, 112, 118, 119, 128, 176  
abnormal 118  
human tumour 128  
irregular 118  
stagnant 19  
Guillain-Barre syndrome 33

## H

Haematological disorder 28  
Hematologic malignancies 120  
Hepatitis 1, 2, 3, 28, 37, 38, 39, 40, 41, 42,  
121  
Highest occupied molecular orbital (HOMO)  
178, 188, 228, 229, 239, 242, 243, 245  
High throughput screening (HTS) 2, 10, 16,  
21, 64, 66, 77, 97  
Hologram quantitative structure-activity  
relationship (HQSAR) 72  
Homeostasis 119, 127, 129  
regulating 129  
tissue 119  
HOMO 179, 242, 245  
energy of 242, 245  
frontier 179  
HOMOdipolarophile 238, 241, 243, 245  
interaction 241  
-LUMOdipole interaction 238, 245  
Homology modeling (HM) 1, 8, 20, 21, 22,  
37, 64, 86, 89, 91  
of proteins 21  
technique 37  
Huckel's molecular orbital theory 176  
Human 120, 126  
adrenocortical adenomas tumour 120  
metabolic pathways 126

## I

Immune 35, 67, 70, 95  
disorders 95  
epitope database 35  
evasion 70  
invasion 67  
Inflammation 98, 120, 121  
decreasing 98

regulation 98  
Inflammatory 98, 121  
  disorders 121  
  process 98  
  active cytokine-related 98  
Inhibitors 36, 40, 41, 68, 83, 87, 91, 93, 94,  
  95, 96, 97, 99, 112, 127, 129, 130  
  antiviral 40  
  competitive 97  
  endogenous 68  
  identified NS5B polymerase 40  
  non-covalent 94  
  non-peptide 97, 99  
  receptor-targeted 112  
Integrals 156, 158, 159, 161, 167  
  dimensional cartesian 156  
  evaluate two-electron 161  
Interactions 11, 22, 35, 68, 118, 125, 132  
  ligand-protein 35  
  protein-ligand 11, 22  
  protein-protein 68, 125, 132  
  receptor-ligand 118  
Inverse electron demand 228, 241, 245, 246  
  reactions 228, 245, 246

## J

JNK-dependent gene transcription factors 117  
Jun-N-terminal kinase (JNK) 116

## K

Kohn-Sham 164, 165, 176, 178  
  equations 165, 176, 178  
  method 164  
Kohn theorem 176, 177  
Koopman's theorem 178, 179

## L

Laplacian of electron density 201, 202, 203,  
  204, 205  
Leishmaniasis 68  
Lewis acids 178, 207  
Lewis's Valence theory 189  
LH 73  
  acceptor domain 73  
  donor domain 73

Ligand based 3, 6, 8, 9, 12, 13, 16, 17, 19, 64,  
  66, 72, 73  
  computational methods 12  
  drug design (LBDD) 3, 6, 8, 9, 12, 13, 16,  
  19, 64, 66, 72, 73  
  virtual screening (LBVS) 17  
Ligands 3, 4, 7, 8, 9, 11, 12, 15, 16, 19, 36, 48,  
  89, 100, 112, 120, 132  
  docked 36  
  identifying small molecule 132  
LigandScout software 47  
Linear combination test (LCT) 123  
Lipinski rule 17, 76  
Lipoprotein 127  
Lowest unoccupied molecular orbital  
  (LUMO) 178, 179, 188, 228, 229, 239,  
  242, 243, 245, 247  
  energy of 179, 242, 245, 247

## M

Material studio program 44  
Mathematical theories 175  
Matrix metalloproteinases 121  
Maybridge database 99  
Mechanism 67, 122, 131, 132, 192, 194, 196,  
  198, 205, 208, 209, 230, 233, 234, 235  
  catalytic 67  
  cellular 132  
  diradical 234  
  regulatory 122  
  stepwise 233, 234, 235  
  stepwise-diradical 233  
  synchronous-concerted 233  
Medicine 28, 111, 112, 122, 132, 175  
  effective 132  
  regenerative 112  
Medium 25, 79  
  cytosolic 79  
  solvent 25  
MEP 153, 154, 167, 169  
  analysis 153  
  evaluation 154, 167  
  implementations 167  
  of large systems 169  
MEP's evaluation 160, 161  
Merck molecular force field (MMFF) 24  
Metabolic pathway databases 125  
MetaCyc metabolic pathway database 126  
Metalloproteases 67

- Methods 19, 37, 66, 123, 124, 125  
  chemotherapy 19  
  complementary 66  
  pathway-based 123, 124, 125  
  statistical 124  
  therapeutic 37
- Middle east respiratory syndrome (MERS) 42
- Mitogen-activated protein kinase (MAPK) 122
- Molecular 15, 29, 30, 31, 41, 43, 63  
  modeling techniques 63  
  operating environment (MOE) 15, 29, 30, 31, 41, 43
- Molecular dynamics 15, 22, 23, 25, 26, 31, 35, 36, 47, 86, 100  
  calculations 25  
  simulations 15, 22, 23, 26, 31, 35, 36, 47, 86, 100
- Molecular orbitals (MO) 27, 175, 176, 217, 229, 239, 245  
  interactions 217  
  method 27
- Multiple 15, 21, 95  
  linear regression 15  
  sclerosis 95  
  template approach 21
- Myocardial infarction 121
- N**
- Natural 39, 84, 195  
  Bond Orbital 195  
  Population Analysis 195  
  Product Database 84  
  products derivatives 39
- Network analysis 111, 123, 124, 125  
  studies 125  
  techniques 124
- Networks 122, 124, 126  
  interacting protein 124  
  metabolic 122  
  probabilistic functional gene 126  
  regulatory 126
- Neurodegeneration 98, 130  
   $\beta$ -amyloid dependent 130
- Neurodegenerative disease (ND) 93, 120  
  age-associated 120
- Neurological damage 96
- Neuronal diseases 121
- Newton's laws 22
- Non-canonical 113, 116, 117, 119, 120  
  pathways 116, 120  
  signalling pathway 113, 116, 117, 119
- Non-covalent interactions 174, 175, 203, 205
- Non-polar cycloadditions 195
- NTPase activity 89
- Nuclei 113, 120, 127, 130, 131, 167, 168, 175, 177, 190, 200, 202, 205, 208, 209  
  atomic 190  
  interacting 205, 208, 209
- Nucleic acids 4, 6, 25, 150
- Nucleocapsid 29, 37
- Nucleophilicity Index 181
- Nucleophile 73, 183, 185, 188, 242, 245  
  attacking cysteine 73  
  marginal 183, 188  
  moderate 183
- Nucleophilic 65, 184, 185  
  hydrolyze 65
- Nucleophilicity 182, 183, 188  
  global 188  
  marginal 183  
  relative 182, 188
- Nucleophilicity index 181, 182, 183  
  relative 182
- Nucleophilicity power 188
- Nucleoprotein 26, 29, 31  
  targeted 31
- O**
- Organogenesis 111
- Osteoporosis 93, 101, 121  
  inflammation 101  
  -pseudoglioma syndrome 121
- OTAVA chemicals 30
- P**
- Parasite 63, 65, 67, 70, 78, 79, 80, 91  
  immunoevasion 63  
  interactions-host 70  
  invasion 67  
  resistance 78
- Parkinson's disease 123
- Pathways 6, 11, 92, 111, 112, 114, 115, 116, 118, 121, 122, 123, 124, 125, 126, 130, 132  
  biochemical 112

- biological 124, 126
  - cellular 112
  - diabetes 130
  - growth control 118
  - intercellular 111, 112
  - intracellular 118
  - metabolic 123, 124
  - multiple discrete 118
  - natural 11
  - signaling 92
  - PCP 117
    - genes 117
    - pathway 117
  - Peptide hydrolysis 80
  - Pharmacological agents 88
  - Pharmacophore 8, 16, 41
    - fingerprints 8
    - placement method 41
    - sites preparation 16
  - Phenol explorer database 45
  - Planar cell polarity (PCP) 116
  - Polyelectrolytes 149, 150
    - natural 150
  - Polymerases 130
  - Porcupine enzyme inhibitors 129
  - Post-translational modifications 150
  - Potential energy surface (PES) 174, 175, 176, 192, 194, 196, 200, 217
  - Predicted protein interactions 126
  - Prestwick database 38
  - Pro-inflammatory cytokines 121
  - Pro-mature domain interaction 68
  - Protease 38, 39, 40, 43, 44, 45, 47, 65, 69, 72, 87, 92, 96, 97
    - enzymes 45
    - helicase enzyme 38
    - human 87
    - lysosomal 92
    - viral 96
  - Protein 8, 68, 97, 100, 122, 125, 132
    - expressions 122
    - flexibility 97, 100
    - protein interactions (PPI) 8, 68, 125, 132
  - Protein data bank & 30, 34, 45
    - NCI database 34
    - PubChem Database 45
    - ZINC Database 30
  - Protein kinase 118, 122
    - mitogen-activated 122
    - monophosphate-activated 122
  - Proteolysis 69
  - Proteolytic enzymes 67
  - Proteomic applications 124
- ## Q
- QM computational methods 28
  - QSAR methodology 13
  - Quantitative structure activity relationships(QSAR) 1, 6, 13, 14, 15, 48, 64
  - Quantum chemistry 150, 151, 152, 153, 166
    - applications 150
    - fields 152
    - scalar 151
  - Quantum 1, 3, 26, 27, 28, 174, 175, 200
    - mechanics (QM) 1, 3, 26, 27, 28
    - theory of atoms in molecules (QTAIM) 174, 175, 200
- ## R
- Rabies 2
  - Rapid overlay of chemical structures (ROCS) 72, 74
  - RCSB protein database 46
  - Reactions 26, 118, 174, 176, 207, 217, 229
    - electrocyclic 174, 207
    - enzymatic 26
    - metabolic 118
    - pericyclic 176, 207, 217, 229
  - Reactivity 174, 187
    - indices for free radicals 187
    - of organic molecules 174
  - Reductase 91
    - thioredoxin glutathione 91
  - Regioselective reaction 210, 212, 215
  - Resources for Pathway-based Analysis 125
  - Rheumatoid arthritis 95, 123
  - RNA 29, 33, 37, 42, 89, 96
    - phosphatase 89
    - polymerase protein 29
    - positive strand 42
    - replication 33, 37
    - single stranded 33, 37
  - Root mean square deviations (RMSD) 40

**S**

Salivary gland tumour 121  
SARS-CoV-2 44, 45, 46  
  proteases 44  
Schizophrenia 121, 123  
Schrödinger's equation 175  
Schrodinger software 43  
Screening 2, 3, 6, 10, 12, 16, 17, 19, 21, 31,  
  36, 47, 48, 64, 66, 160  
  high-throughput 2, 10, 16, 17, 21, 64, 66  
Secreted frizzled-related proteins (SFRPs) 120  
SHAPE-GAUSS score function 74  
Signalling 112, 113, 114, 116, 122, 123, 124,  
  126  
  activity 113  
  cascades 112  
  intracellular 116  
  pathway impact analysis (SPIA) 123, 126  
  upregulating mTOR 114  
Signalling pathways 112, 113, 114, 119, 127  
  canonical Wnt 114, 127  
  dependent 113, 117  
  dependent WNT 114  
  intercellular 112  
  non-canonical Wnt 119  
Signal 20, 124, 125, 180  
  transduction pathway databases 125  
  electrophilicity scale 180  
  gene analysis methods 124  
  gene-based analysis method 124  
  target drugs 20  
Software 9, 13, 15, 16, 22, 39, 43, 45, 47, 83,  
  174, 217, 243  
  commercial 15  
  discovery studio visualizer 45  
  iGEMDOCK 47  
  molecular modelling 174, 217  
Sore throat 28  
Structural stability domains (SSDs) 196  
Structure 3,4, 7, 8, 9, 10, 12, 13, 16, 21, 26,  
  64, 66  
  activity relationships (SAR) 12  
  based computational methods 4  
  based drug design (SBDD) 3, 4, 7, 8, 9, 10,  
  12, 13, 16, 21, 26, 64, 66  
Synthesis 13, 37, 89, 93, 97, 101, 114, 174,  
  208, 216, 229, 233, 242  
  stereochemical 208  
  viral RNA 89

**T**

Tankyrase 111, 130  
Thioredoxin glutathione reductase (TGR) 91  
Thoms' catastrophe theory 196  
Tools 2, 3, 6, 13, 19, 22, 28, 31, 43, 48, 64,  
  65, 124, 125, 126  
  efficient drug discovery 2  
  elements mathematical 13  
  integrated protein annotation 31  
  intuitive bioinformatics 126  
  proteomic data management 124  
  quantum mechanics 28  
  refinement 22  
  toxicity predictions 48  
Topological analysis 174, 189, 190, 196, 200,  
  208, 217  
  applied ELF 190  
  of electron localization function 189  
Toxicity 2, 5, 15, 19, 32, 101  
  biological 2  
Traditional chinese medicine database  
  (TCMD) 30  
*Trypanosoma cruzi* 63, 65, 70  
Trypsinogen 68  
Tuberous sclerosis protein 114

**U**

Universal force field (UFF) 24

**V**

Vaccine 1, 2, 29, 33, 37, 42, 48, 88  
  effective 1, 37  
  efficient 29, 48  
  emergency 29  
  novel 48  
Valence 175, 190  
  basins 190  
  bond theory 175  
Valence basin populations 190  
  calculated 190  
Valproic acid 46  
Vertical 156, 180  
  electron affinities 180  
  ionization potentials 180  
  recurrence relations 156

Vietherb database 45  
Viral diseases 1, 2  
    contagious 1  
    infectious 2  
Virions 37, 42  
Virtual screening 5, 8, 11, 15, 16, 17, 18, 19,  
    36, 37, 40, 64, 65, 66, 100  
    structural based 17  
    campaigns 100  
Virus 19, 38, 39, 40, 97  
    gene 39  
    inhibitors 40  
    NS5A Protein 38  
    proteins 40  
    replication 19, 97  
Viruses 28, 41, 47  
    enveloped RNA 41  
Visual inspection 73, 81, 95  
Visualization 6, 7, 9, 126, 177, 205  
    software 177  
    tools 9, 126

## **W**

Waals forces interaction 25  
Wnt pathways and cancers 120

## **Z**

Zika and corona viruses 2  
Zika virus 19, 33, 37  
    disease 37  
    infections 19, 33  
Zoonotic pathogens 42  
Zwitterionic 190, 191, 208  
    TACs 190, 208  
Zymogen conversion 68



**Zaheer Ul-Haq**

---

Prof. Dr. Zaheer Ul-Haq currently serves as the head of the Computational Chemistry group at the International Center for Chemical and Biological Sciences. Dr. Ul-Haq received a PhD in Organic Chemistry from University of Karachi and obtained his post-doctoral training in theoretical chemistry from University of Innsbruck, Austria. He is an OeAD Fellow, Austria, a Senior Fulbright Fellow, USA, and an Alexander von Humboldt Fellow, Germany. He has more than 15 years of research experience in Computational Chemistry and Computer Aided Drug Design. His research areas include: quantitative structure-activity relationships (QSAR); virtual screening; molecular dynamics simulations; and quantum mechanics. Dr. Ul-Haq has published over 165 research articles and has co-edited a book series entitled, "Frontiers in Computational Chemistry". Currently, he is serving as an editorial board member for the *Journal of Molecular Graphics and Modelling* and *Current Computer-Aided Drug Design*.



**Angela K. Wilson**

---

Angela K. Wilson is John A. Hannah Distinguished Professor of Chemistry at Michigan State University. She has served as Director of the Division of Chemistry at the U.S. National Science Foundation, Associate Vice Provost for Faculty, Regents Professor, and Director of the Center for Advanced Scientific Computing and Modeling at the University of North Texas. She received a Ph.D. in chemical physics from the University of Minnesota. She is a Fellow of the American Chemical Society, American Physical Society, and American Association for the Advancement of Science, and is recipient of the Francis P. Garvan-John M. Olin Medal.